孟鲁司特联合桂龙咳喘宁治疗支气管哮喘

Clinical Study of Montelukast Combined with Guilongkechuanning in the Treatment of Patients with Mild Bronchial Asthma

目的:观察孟鲁司特联合桂龙咳喘宁治疗轻度支气管哮喘的临床疗效。方法:89例非急性发作期轻度哮喘患者随机分为两组,联用组予孟鲁司特10mg,qd,桂龙咳喘宁1.5g,tid。对照组予布地奈德200μg,bid。疗程均为6周。结果:与治疗前相比,两组平均日间哮喘症状评分、血清IL-5水平均有明显降低,肺功能指标FEV1和PEF占预计值的百分比则明显增加,两组间相比差异无统计学意义。两组均未出现严重不良反应。结论:孟鲁司特联合桂龙咳喘宁治疗轻度哮喘具有可靠疗效,无明显不良反应。

Objective： To evaluate and compare the efficacy of montelukast combined with guilongkechuanning and budesonide in the treatment of patients with mild bronchial asthma. Method： 89 mild bronchial asthma cases were randomly divided into two groups. The patients in the montelukast/guilongkechuanning combination group were treated with montelukast 10mg, qd and guilongkechuanning 1.5g, tid. The patients in the budesonide group were treated with budesonide 200ug, bid. Both treatments lasted for 6 weeks. Result：After 6-weeks＇ treatment, daytime symptom scores and serum IL-5 levels were significantly decreased than before the therapy in both groups. At the same time, the lung functional indexes like the rate of FEV1 and PEF to the expected value were obviously higher than before the therapy in both groups. There was no statistical difference in the above indexes between the two groups. The adverse reactions in both groups were rare. Conclu- sion：Montelukast and guilongkechuanning combination were effective and safe in the treatment of patients with mild bronchial asthma.